Quipazine

Source: Wikipedia, the free encyclopedia.
Quipazine
Clinical data
ATC code
  • none
Identifiers
  • 2-piperazin-1-ylquinoline
JSmol)
  • C1CN(CCN1)C2=NC3=CC=CC=C3C=C2
  • InChI=1S/C13H15N3/c1-2-4-12-11(3-1)5-6-13(15-12)16-9-7-14-8-10-16/h1-6,14H,7-10H2 ☒N
  • Key:XRXDAJYKGWNHTQ-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Quipazine is a

scientific research. It was originally intended as an antidepressant but never developed for medical use.[citation needed
]

Pharmacology

Pharmacodynamics

Quipazine is a

agonist, binding to a range of different serotonin receptors, but particularly to the 5-HT2A[2] and 5-HT3 subtypes.[3][4]

Quipazine produces a head-twitch response and other psychedelic-consistent effects in animal studies including in mice, rats, and monkeys.[5] However, it failed to produce psychedelic effects in humans at a dose of 25 mg, which was the highest dose tested due to 5-HT3 mediated side effects of nausea and gastrointestinal discomfort.[6][5] However Alexander Shulgin claimed that a fully effective psychedelic dose could be reached by blocking 5-HT3 receptors using a 5-HT3 antagonist.[7][5]

Chemistry

Quipazine is

2-chloroquinoline with piperazine
.

Quipazine synthesis:[8]

See also

References

  1. PMID 15848758
    .
  2. PMID 7473132
    .
  3. PMID 9513601
    .
  4. PMID 20166948
    .
  5. ^
    PMID 33400504
    .
  6. PMID 8742798
    .
  7. PMID 28224459
    .
  8. ^ DE 2006638, Rodriguez R, issued 1970  Chem. Abstr., 73: 98987g (1970).


Retrieved from "https://en.wikipedia.org/w/index.php?title=Quipazine&oldid=1166942846"